MedTrace Logo

Breath Analysis to Diagnose Lung Cancer

NCT03250390 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1500

Last updated 2025-04-15

No results posted yet for this study

Summary

Determination of volatile organic compounds to discriminate patients with lung cancer from healthy smokers and non-smokers healthy subjects.

Conditions

Interventions

DEVICE

Collection of volatile organic compounds during exhalation

The volatile organic compounds (VOCs) are collected in sorbents at rest and at the end of exhalation according to the concentration of carbon dioxide using ReCIVA breath sampler. The identification of the VOCs will be done by chromatography (Gas Chromatography Mass Spectrometry GC-MS)

Sponsors & Collaborators

  • Institut National de Recherche en Informatique et en Automatique

    collaborator OTHER

  • Institut Pasteur de Lille

    collaborator OTHER

  • Institut MinesTelecom (IMT)

    collaborator UNKNOWN

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Sébastien Hulo, MD · University Hospital, Lille

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-29
Primary Completion
2024-04-29
Completion
2024-04-29

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03250390 on ClinicalTrials.gov